Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 16/20 | 0.52 |
| ▸ | EGFR | P00533 | 15/20 | 0.52 |
| ▸ | ERBB4 | Q15303 | 9/20 | 0.52 |
| ▸ | ERBB3 | P21860 | 8/20 | 0.52 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.47 |
| ▸ | PRKCG | P05129 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
| ▸ | LYN | P07948 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | BLK | P51451 | 1/20 | 0.47 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.47 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.47 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.42 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.42 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5789204 | 0.92 | EGFR (0.45) | ERBB2EGFRERBB4ERBB3CHEK2 | |
| SCHEMBL5788261 | 0.90 | ERBB2 (0.54) | ERBB2EGFRERBB4ERBB3CHEK2 | |
| SCHEMBL6288116 | 0.87 | EGFR (0.49) | ERBB2EGFRERBB4CHEK2PRKCG | |
| SCHEMBL5788156 | 0.82 | ERBB2 (0.50) | ERBB2EGFRERBB4ERBB3CHEK2 | |
| SCHEMBL5786009 | 0.81 | EGFR (0.50) | ERBB2EGFRERBB4ERBB3CHEK2 | |
| SCHEMBL5788794 | 0.80 | ERBB2 (0.53) | ERBB2EGFRERBB4ERBB3CHEK2 | |
| SCHEMBL5785992 | 0.80 | ERBB2 (0.50) | ERBB2EGFRERBB4ERBB3 | |
| SCHEMBL5786193 | 0.80 | ERBB2 (0.55) | ERBB2EGFRERBB4ERBB3 | |
| SCHEMBL5787215 | 0.80 | ERBB2 (0.45) | ERBB2EGFRERBB4ERBB3LCK | |
| SCHEMBL5787543 | 0.79 | EGFR (0.71) | ERBB2EGFRERBB4CHEK2PRKCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1249451-B1 | Bicyclic-substituted 4-amino-pyridopyrimidine derivatives | PFIZER PROD INC (US) | 2006-06-21 | — | — | EP | claimed |
| US-6927220-B2 | Antiproliferative and antitumor agents | PFIZER INC (US) | 2005-08-09 | — | — | US | claimed |
| US-20030045535-A1 | Bicyclic-substituted 4-amino-pyridopyrimidine derivatives | PFIZER INC. | 2003-03-06 | — | — | US | claimed |
| EP-1249451-B1 | Bicyclic-substituted 4-amino-pyridopyrimidine derivatives | PFIZER PROD INC (US) | 2006-06-21 | — | — | EP | disclosed |
| US-6927220-B2 | Antiproliferative and antitumor agents | PFIZER INC (US) | 2005-08-09 | — | — | US | disclosed |
| US-20030045535-A1 | Bicyclic-substituted 4-amino-pyridopyrimidine derivatives | PFIZER INC. | 2003-03-06 | — | — | US | disclosed |
| EP-1249451-A2 | Bicyclic-substituted 4-amino-pyridopyrimidine derivatives | Pfizer Products Inc. (US) | 2002-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045535-A1 | Bicyclic-substituted 4-amino-pyridopyrimidine derivatives | CDK4, TYMP, CDK6 | ERBB2 389/4885EGFR 630/4885ERBB4 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.